NY-ESTEE-LAUDER
18.6.2020 15:41:12 CEST | Business Wire | Press release
Today, The Estée Lauder Companies (NYSE:EL) announced that Michelle Freyre will join The Estée Lauder Companies as Senior Vice President, Global General Manager, Clinique, effective July 1, 2020. She will report to John Demsey, Executive Group President, The Estée Lauder Companies (ELC), and will succeed Jane Lauder, who has been appointed Executive Vice President, Enterprise Marketing and Chief Data Officer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200618005556/en/
In her new role leading Clinique, Michelle will be responsible for guiding the brand’s overall strategic vision, including innovation, product development and marketing, and all facets of consumer and digital engagement. She will partner closely with members of the global Clinique leadership team to continue brand momentum by driving consumer relevance globally and connecting emotionally with consumers throughout their beauty journey. Michelle and her team will also work to imagine the future of the retail experience, including Clinical Reality, Virtual Selling and High Touch services.
Michelle joins The Estée Lauder Companies from Johnson & Johnson, where she had an impressive 20-year career holding various leadership roles within its Consumer Health Products division, most recently serving as President, U.S. Beauty. In this role, she was responsible for the company’s portfolio of beauty brands at the time, including Neutrogena, Aveeno, Clean & Clear and RoC, and led the successful performance of many brands. Notably, she successfully transformed the image of Johnson & Johnson Beauty with a fully re-imagined Celebrity Talent & Influencer Strategy, diversifying the talent portfolio to reflect a more integrated approach.
“Michelle is a dynamic leader with deep experience across beauty, including marketing, innovation, sales, consumer engagement and strategic growth,” said Mr. Demsey. “She is particularly adept at finding new and innovative ways to fuel growth by exceeding consumer expectations and pushing the boundaries of possibility. She is a wonderful fit for Clinique, and I am thrilled to welcome her to the brand.”
Jane Lauder added, “I could not be happier that Michelle is joining Clinique. She has a tremendous track record of driving successful beauty brands, and her passion for surprising and delighting the global consumer is unparalleled. The Clinique team is lucky to have her as a leader, and I know the brand will be in wonderful hands with her at the helm.”
Prior to her role as President, U.S. Beauty, she served as the General Manager of Neutrogena, the largest brand within Johnson & Johnson’s Consumer division, and as the leader of the company’s Los Angeles campus. During her tenure, she strengthened brand leadership positions in facial care and sun care by focusing on core hero products and franchises and disruptive innovation across categories.
Michelle is passionate about talent development and has a proven track record of fostering workplaces that embrace inclusion and diversity, strengthening the talent pipeline at Johnson & Johnson with high-potential, diverse leaders. She has received several awards and honors in recognition of her exceptional career, including being named to Fortune’s 2018 “50 Most Powerful Latinas in Business.” Additionally, she sits on the Board of Directors of Cynosure, LLC, and is a founding member of CHIEF, a private network designed to accelerate women in business and support women leaders.
About The Estée Lauder Companies Inc.
The Estée Lauder Companies Inc. is one of the world’s leading manufacturers and marketers of quality skin care, makeup, fragrance and hair care products. The company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Prescriptives, Lab Series, Origins, Tommy Hilfiger, M·A·C, Kiton, La Mer, Bobbi Brown, Donna Karan New York, DKNY, Aveda, Jo Malone London, Bumble and bumble, Michael Kors, Darphin, Tom Ford, Smashbox, Ermenegildo Zegna, AERIN, RODIN olio lusso, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, By Kilian, BECCA, Too Faced and Dr. Jart+.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200618005556/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
REPLY: The Board of Directors Approved the Draft Financial Statements for the Year 202512.3.2026 15:38:00 CET | Press release
All economic indicators are positive.Consolidated turnover of €2,483.6 million (€2,300.5 million in 2024);EBITDA at €467.6 million (€410.6 million in 2024);EBIT at €391.7 million (€330.4 million in 2024)Group net profit at €250.9 million (€211.1 million in 2024)Approval of the proposed dividend distribution of €1.35 per share. Today the Board of Directors of Reply S.p.A. [MTA, STAR: REY] approved the draft financial statement for the year 2025, which will be submitted for approval to the Shareholders’ Meeting to be held in first call in Turin on 23 April 2026. The Reply Group closed 2025 with a consolidated turnover of €2,483.6 million, an increase of 8.0% compared to €2,300.5 million in 2024. All indicators are positive for the period. Consolidated EBITDA was €467.6 million, an increase of 13.9% compared to €410.6 million at December 2024. EBIT, from January to December, was at €391.7 million, which is an increase of 18.5% compared to €330.4 million at December 2024. The Group net pro
LZE GmbH Introduces Fraunhofer’s RFicient® Technology to the Market12.3.2026 14:51:00 CET | Press release
LZE GmbH is expanding its technology transfer portfolio and making the RFicient® ultra-low-power wake-up receiver technology from the Fraunhofer Institute for Integrated Circuits IIS available for the first time as a standard chip for close-to-production industrial applications. The solution enables energy-efficient IoT designs that remain continuously reachable while consuming only microamps – a key step for long-lasting, low-maintenance IoT products. LZE GmbH drives technology transfer to market: standard chip availability for close-to-production applications As a bridge between research and industry, LZE GmbH is making it easier for companies to access innovative technologies and helping them to quickly and reliably transform new developments into market-ready solutions. With RFicient®-IC (FH101RF), LZE is providing another high-tech product that comes directly from Fraunhofer research and can now be ordered in volume and integrated into close-to-production product development for t
Owkin Creates New Spin out Waiv, Formerly Owkin Dx, With $33M Financing12.3.2026 14:30:00 CET | Press release
Investment lead by OTB Ventures and Alpha Intelligence CapitalWaiv develops AI-powered precision testing to better identify and stratify patients in the clinic and in clinical trials, transforming patient careWaiv extends Owkin’s strategy of real-world validation for its AI Owkin, the AI company on a mission to solve the complexity of biology, today announced the spin out of Waiv, formerly known as Owkin Dx. The move follows significant investor interest and positions Waiv to bring AI-powered precision testing for better identification of patients in the clinic and in clinical trials, to transform patient care. This follows on from the successful launch of Bioptimus, an Owkin incubated company, in February 2024. Waiv translates AI innovation into real-world clinical impact, developing tests that predict biomarkers and patient outcomes, including RlapsRisk BC for prognostic risk profiling. With multiple tests already in use in clinical settings, its deployment platform Destra, and colla
RQM+ Launches SMART Solutions Life Cycle Partnership Model12.3.2026 14:30:00 CET | Press release
Helps MedTech Companies Navigate MDR, IVDR, and AI-Enabled Device Development RQM+, a leading MedTech CRO offering regulatory consulting, clinical trial, laboratory, and reimbursement services, today announced the launch of SMART Solutions, a life cycle partnership model designed to help medical device and diagnostics companies manage growing regulatory and development complexity. SMART Solutions introduces a strategy-led operating framework that unifies regulatory, quality, clinical, reimbursement, and laboratory expertise to support MedTech companies across the entire product life cycle to help reduce risk from early development through post-market. “MedTech companies are navigating unprecedented complexity as regulatory expectations evolve, product innovation accelerates, and post-market expectations are expanding,” said John Potthoff, Ph.D., chief executive officer of RQM+. “SMART Solutions moves beyond traditional consulting by providing an integrated life cycle partnership that h
Cryptio Raises $45m Series B as Digital Assets Move Into Regulated Financial Markets12.3.2026 14:06:00 CET | Press release
The system of record for tokenized finance – ERP infrastructure for institutions operating in digital assets Cryptio, a leader in financial data transformation and enterprise resource planning (ERP) applications for regulated digital assets, announced today a $45 million Series B funding round co-led by BlackFin Capital Partners and Sentinel Global, with participation from 1kx, Alven, BlueYard Capital and Ledger Cathay Capital. Banks, exchanges, asset managers, including Société Générale’s SG Forge, Circle, Gemini, and Securitize rely on Cryptio to ensure financial integrity across their digital assets businesses. Existing ERP systems fall short for digital assets Traditional ERP and accounting systems were not designed for blockchain-native assets, real-time reporting, or modern custody frameworks. As regulated financial institutions expand into stablecoins, tokenized securities and other on-chain instruments, these limitations create material operational and reporting challenges. Cry
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
